1. Inicio
  2. Publicaciones
  3. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis

Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Hernández-Boluda J.-C.
  • Pastor-Galán I.
  • Arellano-Rodrigo E.
  • Raya J.-M.
  • Pérez-Encinas M.
  • Ayala R.
  • Ferrer-Marín F.
  • Velez P.
  • Fox M.-L.
  • Hernández-Rivas J.-M.
  • Xicoy B.
  • Mata-Vázquez M.-I.
  • García-Fortes M.
  • Pérez-López R.
  • Angona A.
  • Cuevas B.
  • Senín A.
  • Ramírez M.-J.
  • Ramírez-Payer A.
  • Gómez-Casares M.-T.
  • Martínez-Valverde C.
  • Magro E.
  • Steegmann J.-L.
  • Durán M.-A.
  • García-Hernández C.
  • Gasior M.
  • de Villambrosia S.G.
  • Alvarez-Larrán A.
  • Pereira A.

Grupos

Abstract

Available data have proved insufficient to develop consensus recommendations on the prevention of thrombosis and bleeding in myelofibrosis (MF). We evaluated the incidence and risk factors of vascular complications in 1613 patients from the Spanish Myelofibrosis Registry. Over a total of 6981 patient-years at risk, 6.4% of the study population had at least one thrombotic event after MF diagnosis, amounting to an incidence rate of 1.65 per 100 patient-years. Prior history of thrombosis, the JAK2 mutation, and the intermediate-2/high-risk International Prognostic Scoring System (IPSS) categories conferred an increased thrombotic risk after adjustment for the risk-modifying effect of anti-thrombotic and cytoreductive treatments. History of thrombosis and the JAK2 mutation allowed us to pinpoint a group of patients at higher risk of early thrombosis. No decreased incidence of thrombosis was observed while patients were on anti-thrombotic or cytoreductive treatment. An increased risk of venous thrombosis was found during treatment with immunomodulatory agents. A total of 5.3% of patients had at least one episode of major bleeding, resulting in an incidence rate of 1.5 events per 100 patient-years. Patients in the intermediate-2/high-risk IPSS categories treated with anti-coagulants had an almost sevenfold increased risk of major bleeding. These findings should prove useful for guiding decision-making in clinical practice. © 2022 British Society for Haematology and John Wiley & Sons Ltd.

Datos de la publicación

ISSN/ISSNe:
0007-1048, 1365-2141

BRITISH JOURNAL OF HAEMATOLOGY  WILEY

Tipo:
Article
Páginas:
529-538
PubMed:
36089912
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,677 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Hemorrhage; Humans; Primary Myelofibrosis; Registries; Risk Factors; Thrombocythemia, Essential; Thrombosis; acenocoumarol; acetylsalicylic acid; anticoagulant agent; antithrombocytic agent; calreticulin; hemoglobin; hydroxyurea; Janus kinase 2; Janus kinase inhibitor; lenalidomide; low molecular weight heparin; pomalidomide; ruxolitinib; thalidomide; thrombopoietin receptor; adult; aged; artery thrombosis; Article; bleeding; cardiovascular risk factor; controlled study; diabetes mellitus; female; heart arrhythmia; heart failure; hepatomegaly; human; hypercholesterolemia; hypertension; leukocyte count; leukocytosis; major clinical study; male; myelofibrosis; myeloproliferative neoplasm; platelet count; polycythemia vera; prediction; risk factor; smoking; splenomegaly; thrombocyte; thrombocythemia; thrombocytosis; thrombosis; ultrasound; vein thrombosis; bleeding; complication; genetics; myeloid metaplasia; register; thrombocythemia; thrombosis

Campos de Estudio

Cita

Compartir